Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636152 · ClinicalTrials.gov registry record · Phase 2
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT03636152: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT03636152 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03636152, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD. This study assesses a novel therapy (hydroxychloroquine, HCQ) for the treatment of CVD in patients with CKD. This is the first human proof-of-concept study and is planned to be conducted among US Veterans, who suffer from both CKD and CVD at a disproportionately greater rates. The outcome of this study has the potential to provide an entirely new line of therapy for the treatment of CVD in CKD.
Interventions
- DRUG Matching Placebo
- DRUG Hydroxychloroquine
- PROCEDURE MRI carotid
- PROCEDURE APWV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636152
The ClinicalTrials.gov registry entry for NCT03636152 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Matching Placebo is the first listed.
NCT03636152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03636152 about?
NCT03636152 is a clinical study titled "Management of Cardiovascular Disease in Kidney Disease (MaCK) Study". Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD. This study assesses a novel therapy (hydroxychloroquine, HCQ) for the treatment of ...
What is the current status of trial NCT03636152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-12-14. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT03636152?
The interventions under investigation include: Matching Placebo (DRUG), Hydroxychloroquine (DRUG), MRI carotid (PROCEDURE), APWV (PROCEDURE).
Who is sponsoring clinical trial NCT03636152?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.